NPO 13

Drug Profile

NPO 13

Alternative Names: NPO-13

Latest Information Update: 22 May 2015

Price : $50

At a glance

  • Originator Nihon Pharmaceutical
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastrointestinal disorders

Most Recent Events

  • 22 May 2015 Nihon Pharmaceutical completed phase-II clinical trials in Gastrointestinal disorders (Diagnosis) in Japan (Intraluminal) (NCT02265939)
  • 01 Oct 2014 Phase-II clinical trials in Gastrointestinal disorders (Diagnosis) in Japan (Intraluminal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top